Results 1 to 10 of about 516 (139)

Challenges in schizoaffetive disorder therapeutic – a case report of a patient with hiperprolactinemia [PDF]

open access: yesEur Psychiatry, 2021
Introduction The only FDA approval therapeutic for schizoaffective disorder is paliperidone. Hiperprolactinemia is one of the most frequent side effects induced by first generation antipsychotics (FGA) or by second generation antipsychotic (SGA), such as
Rodrigues D   +3 more
europepmc   +4 more sources

[Narcolepsy secondary to a rare fatal disease]. [PDF]

open access: yesRev Neurol, 2023
Fontana-García N   +5 more
europepmc   +1 more source

Langerhans cell histiocytosis: Case report and literature review [PDF]

open access: yesBiomedica, 2021
Medina MÁ   +3 more
europepmc   +1 more source

[Erdheim-Chester disease: a rare histiocytosis with outstanding response to cobimetinib.] [PDF]

open access: yesRev Fac Cien Med Univ Nac Cordoba, 2021
Sosa GA   +5 more
europepmc   +1 more source

[Hip fractures in patients treated with antipsychotic drugs. Study of retrospective cohorts in Catalonia]. [PDF]

open access: yesAten Primaria, 2022
González Tejón S   +5 more
europepmc   +1 more source

The role of cannabinoids in neurodevelopmental disorders of children and adolescents. [PDF]

open access: yesRev Neurol, 2022
Dias-de Freitas F   +5 more
europepmc   +1 more source

Position Statement on Ischemic Heart Disease - Women-Centered Health Care - 2023. [PDF]

open access: yesArq Bras Cardiol, 2023
Oliveira GMM   +51 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy